Growth-hormone-derived peptide studied for effects on fat metabolism
Clinical research
Read the profile Peptide profile
Retatrutide
Also known as LY3437943
GIP, GLP-1 and glucagon receptor agonist
Clinical research
Science, with its context intact.What to knowThe evidence
The evidence
in perspective.
Human obesity trials investigate this triple agonist. Trial findings do not establish FDA approval. FDA states that retatrutide cannot be used in compounding under federal law.
View the supporting source- Research area
- Metabolic
- Biological target or mechanism
- GIP, GLP-1 and glucagon receptor agonist
- Evidence context
- Clinical research
- Availability
- Reference only. Not available for compounding.
From information to a conversationClinical decisions stay
Clinical decisions stay
with clinical professionals.
This profile is a research reference. Your prescriber and pharmacy assess the relevant clinical and dispensing pathway. Inclusion here is not an offer to sell this compound.
